Figure 12.

Activation chart of MAPK pathway (Biocarta) shown as an interacting network. MAPK pathway components activation compared with no-drug conditions are shown for: (a) Cetuximab-only treatment; (b) Cetuximab core gene group; (c) Erlotinib-only treatment; (d) Erlotinib core gene group. MAPK pathway activation in the presence of human blood serum only treatment, (e); in combination with cetuximab, (f); and in combination with erlotinib, (g), are shown. MAPK pathway activation in the presence of EGF-only treatment, (h); in combination with cetuximab, (i); and in combination with erlotinib, (j), are shown. MAPK pathway activation in the presence of EGF-only treatment and in combination with cetuximab or erlotinib is shown in panel F. MAPK pathway activation level (PAL) is indicated for each gene group. Green/red arrows indicate activation/inhibition interactions, respectively. The color depth of transcript nodes reflects the extent of node activation (natural logarithms of the expression fold change for each node, the reference is the geometric average between expression levels in all samples in the respective groups). Green stands for activation, red stands for inhibition, white stands for non-differential expression.